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Background
Only a fraction of patients with metastatic colorectal
cancer (mCRC) receive clinical benefit from therapy
with anti-epidermal growth factor receptor (EGFR) anti-
bodies. Gene mutations along the Ras pathway (KRAS,
NRAS, BRAF, PIK3CA) correlate with poor response to
anti-EGFR antibodies.
Patients and methods
By implantation and serial propagation in NOD/SCID
mice, we produced large xenograft cohorts from 85
patient-derived mCRC samples ("xenopatients”).
Results
Xenopatients retained the histological and genomic
features of the original counterparts, responded to the
anti-EGFR antibody cetuximab similarly to clinical obser-
vations, and could be prospectively stratified as responders
or nonresponders based on predictive biomarkers. Geno-
type-response correlations indicated HER2 amplification
specifically in a subset of cetuximab-resistant, KRAS/
NRAS/BRAF/PIK3CA wild-type cases. In this subset, com-
bined HER2/EGFR inhibition induced long-lasting tumor
regression. We also assessed the effects of MEK and PI3K/
mTor inhibitors (AZD6244 and BEZ235 respectively) in
40 specimens harboring KRAS/ NRAS/BRAF/PIK3CA
mutations. Cotreatment of xenografts with AZD6244
+BEZ235 induced disease stabilization in the majority of
cases (70%) but did not lead to tumor regression. Mono-
therapy was less effective, with BEZ235 displaying higher
activity than AZD6244. Triple therapy with cetuximab
provided further advantage. The extent of disease control
declined upon prolonged treatment.
Conclusions
Our preclinical platform prospectively recapitulated bio-
marker-based case stratification and was instrumental in
identifying HER2 as a predictor of resistance to cetuximab
and of response to combination therapies against HER2
and EGFR. The prevalent growth-suppressive effects pro-
duced by MEK and PI3K/mTOR inhibition suggest that
this strategy may retard disease progression in KRAS-
mutant mCRC patients.
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